Novo Nordisk Cuts US List Prices for GLP-1 Drugs; Stock Continues to Fall

FROM 1 minute ago

Novo Nordisk (NVO) is slashing U.S. list prices for its GLP-1 medications. The move is not reversing its stock slide.

U.S.-listed shares of Novo Nordisk fell about 3.5% in premarket trading Tuesday, a day after they sank 16% to their lowest level in nearly five years after the Danish firm’s CagriSema obesity treatment delivered less weight loss than that of Eli Lilly’s (LLY) Zepbound.

Before the bell, Novo Nordisk said that effective Jan. 1, 2027, it would lower the list price of Wegovy 2.4-mg injection and 25-mg tablets, Ozempic 0.5-mg, 1-mg, and 2-mg injections, and Rybelsus 7-mg or 14-mg tablets to $675. That would represent reductions from the current list price of approximately 50% and 35% for Wegovy and Ozempic, respectively.

The move “addresses access barriers to our innovative medicines, especially for patients whose out-of-pocket costs are linked to list price,” Novo Nordisk said, adding that the “changes in list price do not have an impact on direct-to-patient, self-pay prices.”

U.S.-listed shares of Novo Nordisk entered the day having lost 56% of their value over the past 12 months. Lilly shares slipped about 1.5% before the bell but have gained 20% over the past year.

Here’s How Much Salesforce Stock Is Expected to Move After Earnings Wednesday

FROM 46 minutes ago

Salesforce is slated to report earnings after the market closes on Wednesday, with traders anticipating a big move from the software giant’s stock in the days that follow.

Based on current options pricing, traders expect Salesforce (CRM) stock could swing up to 9% in either direction by the end of the week. A move of that magnitude from Monday’s close could bring the stock back above $194, recovering some of its recent losses, or drag it down to $162, its lowest level in three years.

Salesforce’s stock has lost about a third of its value since the start of the year amid a broader rout in software stocks after new AI tools from Anthropic added fuel to worries about the technology’s potential to disrupt the industry. 

Analysts at UBS and Oppenheimer recently cut their price targets for Salesforce to $200 and $275, respectively, ahead of Wednesday’s results. They suggested Salesforce’s growth could be muted in the short term as the company faces some headwinds from growing competition and field checks suggested customers may be watching their spending.

Salesforce is seen reporting adjusted earnings per share of $3.05 on a 12% year-over-year jump in revenue to a record $11.18 billion for the fourth quarter, according to estimates compiled by Visible Alpha.

Analysts have largely stayed bullish on Salesforce despite the software giant’s recent slump. Of the 20 analysts with current ratings tracked by Visible Alpha, 15 have “buy” or equivalent ratings compared to five “hold” ratings. Their average price target of $313 would imply upside of more than 75% from Monday’s close.

–Aaron McDade

AMD Stock Soars on Massive AI Chips Deal With Meta

FROM 1 hr 13 min ago

As part of a massive deal for AI computing power, Meta Platforms may wind up owning up to roughly 10% of Advanced Micro Devices’ stock. AMD investors evidently are enthusiastic about the news.

AMD (AMD) shares soared 10% in premarket trading Tuesday after the semiconductor giant inked a deal with Meta (META) to provide the Facebook and Instagram parent with 6 gigawatts of AMD Instinct GPUs to power its AI infrastructure.

Financial terms weren’t disclosed but The Wall Street Journal reported the deal was worth more than $100 billion.

The companies said that shipments supporting the first gigawatt deployment are set to begin in the second half of 2026.

As part of the transaction, Santa Clara, Calif.-based AMD issued Meta a performance-based warrant for up to 160 million shares of its stock, “structured to vest as specific milestones associated with Instinct GPU shipments are achieved.” AMD currently has just over 1.6 billion outstanding shares.

“We’re excited to form a long-term partnership with AMD to deploy efficient inference compute and deliver personal superintelligence,” Meta founder and CEO Mark Zuckerberg said. “This is an important step for Meta as we diversify our compute. I expect AMD to be an important partner for many years to come.”

AMD shares entered the day down about 8% year-to-date, having dropped sharply earlier this month despite reporting strong quarterly results. Meta shares, which are down roughly 3.5% in 2026, edged lower before the bell, while AMD rival Nvidia (NVDA), which reports its highly anticipated earnings Wednesday, slipped more than 1%.

Stock Futures Edge Higher After Indexes Tumble on Tariff Uncertainty, AI Disruption Concerns

FROM 2 hr 20 min ago

Futures contracts connected to the Dow Jones Industrial Average pointed 0.3% higher.

S&P 500 futures were up 0.2%.

Nasdaq 100 futures also were up 0.2%.

Netflix Stock Drops as Trump Sets Sights on Director Susan Rice

FROM 5 minutes ago

The President didn’t exactly weigh in on the Netflix-Warner Bros. Discovery deal over the weekend. But it looked enough like he did that he’s moving markets today.

Shares of Netflix (NFLX) were recently dropping following a statement on Truth Social that said the streaming video giant “should fire” Susan Rice, a member of its board of directors who also served the past three Democratic presidents. President Donald Trump’s Saturday post did not specifically mention Netflix’s planned acquisition of Warner Bros. (WBD), but it responded to another person’s post, which advocated against it.

That seemed to inflame investor concern that the Netflix-Warner Bros. deal, its future already uncertain after negotiations with competing Warner suitor Paramount Skydance (PSKY) were reopened last week—might face challenging regulatory obstacles.

The White House did not provide an additional statement to Investopedia in time for publication, and Netflix didn’t respond to a request for comment. Rice could not be reached in time for publication. An updated bid from Paramount Skydance is expected sometime today.

Read the full article here.

–David Marino-Nachison

Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here’s Why

FROM 1 hr 28 min ago

The weight-loss drug wars took a fresh turn on Monday.

Shares of Novo Nordisk (NVO) were down over 15% in recent trading after the Danish drugmaker announced the results of a clinical trial for its new weight-loss drug that came in short of expectations.

Novo Nordisk said that among a group of 809 people, the average weight loss for a patient taking its in-development drug CagriSema was about 23% of a patient’s body weight after 84 weeks. That was lower than the 25.5% mark for those in the trial that took tirzepatide, the active ingredient in Eli Lilly’s (LLY) Mounjaro and Zepbound.

The result marks the latest CagriSema trial to drag on sentiment surrounding the Ozempic and Wegovy maker’s stock amid growing worries about competition from rival Eli Lilly.

Read the full article here.

–Aaron McDade

Arcellx Stock Skyrockets as Biotech Acquired by Gilead Sciences

FROM 1 hr 54 min ago

Monday has been an awful day for equities investors thus far. Not so for Arcellx shareholders.

Arcellx (ACLX) stock skyrocketed 77% after the biotech firm entered into an agreement to be acquired by Gilead Sciences (GILD) for $115 per share in cash and one contingent value right of $5 per share, or $7.8 billion.

Arcellx shares, which closed at $64.11 each Friday, were trading around $114 recently. They had been little changed over the past 12 months until today.

Arcellx and Kite, a Gilead company, already were collaborating to co-develop and co-commercialize Arcellx’s anitocabtagene autoleucel (anito-cel), which treats patients with multiple myeloma. 

“This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma,” Gilead CEO Daniel O’Day said. “Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy.”

The companies anticipate the deal will close in the second quarter.

Blizzard Cancels Thousands of Flights Across East Coast

FROM 3 hr 59 min ago

The snowstorm currently working its way across the East Coast is wreaking havoc on air travel, with over 5,300 flights cancelled in the U.S. already for Monday alone, per the flight tracking website FlightAware.

There were more than 7,500 delays and 3,400 cancellations on Sunday as the storm started to batter the coast.

Cancellation rates are near or above 90% at several airports including New York’s John F. Kennedy International and LaGuardia, and Boston Logan International, among others.

Shares of major airlines were lower before the bell, with United Airlines (UAL) and American Airlines (AAL) each down about 1%, while Delta Air Lines (DAL) slipped 0.5%.

–Aaron McDade

Domino’s Pizza Stock Surges on Revenue, Same-Store Sales Beat

FROM 4 hr 36 min ago

Domino’s Pizza CEO Russell Weiner says the company’s “Hungry for MORE” strategy is paying off.

Shares of Domino’s (DPZ) surged 6% before the bell Monday after the Ann Arbor, Mich.-based pizza giant reported better-than-expected revenue and same-store sales.

Domino’s posted fiscal 2025 fourth-quarter revenue of $1.54 billion, up 6.4% year-over-year and topping the consensus $1.52 billion estimate of analysts surveyed by Visible Alpha.

Same-store sales growth of 3.7% easily topped expectations of 2.0%, although earnings per share of $5.35 came up just short of estimates.

“In 2025 we demonstrated that when we execute our Hungry for MORE strategy it delivers MORE sales, MORE stores, and MORE profits,” Weiner said, referring to the company’s five-year plan to “grow and win as a brand.”

Domino’s board approved a 15% quarterly dividend increase to $1.99 per share, to be paid on March 30 to shareholders of record as of March 13.

Domino’s shares entered Monday down nearly 8% this year and 17% over the past 12 months.

Home Depot and Lowe’s Report Earnings This Week. Here’s How Much the Stocks Are Expected to Move

FROM 5 hr 30 min ago

Home Depot and Lowe’s are set to report earnings this week, with traders anticipating sizable swings in the home improvement retailers’ stocks following the results.12

Home Depot is set to report earnings on Tuesday morning, with rival Lowe’s following Wednesday. Current options pricing suggests traders expect Home Depot (HD) stock could move up to 4% in either direction by the end of the week, while Lowe’s (LOW) could swing up to 5%.

For Home Depot, a shift of that size from Friday’s close could lift the stock above $398, its highest level since last September, or drag the stock down to $366. For Lowe’s, the move could mean setting a record high above $294 at the high end, or dropping as low as $266.

Both stocks have enjoyed a strong start to the year so far, with Home Depot gaining about 11% and Lowe’s up 16% for 2026, amid a broader rotation out of tech stocks in favor of consumer-focused companies.

Read the full article here.

–Aaron McDade

Stock Futures Fall Amid Tariffs Uncertainty

FROM 6 hr 5 min ago

Futures contracts connected to the Dow Jones Industrial Average pointed 0.3% lower.

S&P 500 futures also were down 0.3%.

Nasdaq 100 futures declined 0.5%.